Patent intelligence · US
US 11993644
Antigen binding molecules targeting SARS-CoV-2
Antigen binding molecules targeting SARS-CoV-2
Patent details — US 11993644
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 28, 2024
- Expiration
- May 23, 2044
- Applicant
- Generate Biomedicines, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/13
Quick answer
US 11993644 (Antigen binding molecules targeting SARS-CoV-2) is held by Generate Biomedicines, Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Generate Biomedicines, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K31/13, A61K31/215, A61K31/45
Frequently asked questions
What is US patent 11993644?
US 11993644 (Antigen binding molecules targeting SARS-CoV-2) is held by Generate Biomedicines, Inc.. Status: granted. Granted May 28, 2024. Expires May 23, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11993644?
Generate Biomedicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11993644 expire?
Our index shows an expiration date of May 23, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.